title: [Profile of the effect of succinylcholine after pre-curarization with atracurium, vecuronium or pancuronium].
abstract: OBJECTIVE
  The depolarizing muscle relaxant succinylcholine (SCh) may cause several side effects including muscle fasciculations and postoperative myalgia. These can be attenuated or even prevented by prior administration of a non-depolarizing muscle relaxant. A study was conducted to detect any difference between clinically established approaches concerning the successful prevention of muscular side effects and the influence on the time profile of SCh action.
  
  
  METHODS
  The study included 64 patients (ASA status I or II) who underwent elective surgery under general anesthesia. The patients were divided into four groups; the demographic data did not differ significantly between the groups (see table 1). Before the injection of SCh (1 mg/kg) for intubation, the control group received saline (K), the other groups 5 mg Atracurium (A), 1 mg Vecuronium (V), or 1 mg Pancuronium (P), respectively. Neuromuscular block was quantified after train-of-four (TOF) stimulation of the tibial nerve by accelerometry at the toe. The first response was used to determine the onset time, duration of effect, and recovery index. It was noted whether SCh led to muscular activity. Postoperatively, patients were asked whether they experienced any muscular sequelae. Statistical significance was assessed at the 5% probability level by the Mann-Whitney-U test and the CHi2 test (Fisher's exact test, if appropriate).
  
  
  RESULTS
  SCh caused a complete neuromuscular block in all patients. Most patients in the control group exhibited muscular contractions than in the other groups (see table 2), but only two patients reported light myalgia. There was no statistically significant difference between the four groups in the onset time and the recovery index of SCh. The duration of the effect was significantly reduced by atracurium (7.5 min) or vecuronium (8.2 min) as compared to the placebo (11.8 min) and pancuronium (13.5 min) (see figure).
  
  
  CONCLUSIONS
  The prolonged duration of the SCh effect after pancuronium is probably due to the known inhibition of cholinesterase by pancuronium. The short duration of action after Atracurium and Vecuronium can be explained by the competitive antagonism at the receptor causing an increased amount of unbound SCh. The duration of the SCh effect may be influenced according to clinical needs by the choice of the non-depolarizing muscle relaxant. The significantly reduced duration of complete neuromuscular block after Atracurium or Vecuronium as precurarizing agents may be advantageous in cases where a fast recovery of spontaneous breathing is essential. If a reduction of the SCh blockade has to be avoided, Pancuronium should be selected for prior administration.
authors.affiliation: Klink und Poliklinik für Anästhesiologie und Spezielle Intensivmedizin, Rheinischen Friedrich-Wilhelms-Universität Bonn.
authors.forename: B J
authors.initials: BJ
authors.lastname: Ebeling
authors.forename: T
authors.initials: T
authors.lastname: Keienburg
authors.forename: D
authors.initials: D
authors.lastname: Hausmann
authors.forename: C
authors.initials: C
authors.lastname: Apffelstaedt
mesh_terms: D000328:Adult; D000768:Anesthesia, General; D001279:Atracurium / Q000008:administration & dosage* / Q000009:adverse effects; D004576:Electromyography / Q000187:drug effects*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009119:Muscle Contraction / Q000187:drug effects; D009467:Neuromuscular Depolarizing Agents / Q000008:administration & dosage* / Q000009:adverse effects; D009469:Neuromuscular Junction / Q000187:drug effects; D003473:Neuromuscular Nondepolarizing Agents / Q000008:administration & dosage* / Q000009:adverse effects; D010197:Pancuronium / Q000008:administration & dosage* / Q000009:adverse effects; D011183:Postoperative Complications / Q000139:chemically induced / Q000517:prevention & control; D011229:Preanesthetic Medication; D013390:Succinylcholine / Q000008:administration & dosage* / Q000009:adverse effects; D014673:Vecuronium Bromide / Q000008:administration & dosage* / Q000009:adverse effects
chemical_list: D009467:Neuromuscular Depolarizing Agents; D003473:Neuromuscular Nondepolarizing Agents; D001279:Atracurium; D014673:Vecuronium Bromide; D013390:Succinylcholine; D010197:Pancuronium
vernacular_title: Das Wirkungsprofil von Succinylcholin nach Präcurarisierung mit Atracurium, Vecuronium oder Pancuronium.